Middle East Liquid Biopsy Market AI-Powered Genomic Testing
According to Shivani Zoting, who specializes in advanced cancer diagnostics solutions, liquid-based genomic testing, and non-invasive molecular diagnostics, with 5+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the Middle East liquid biopsy market. The global Middle East liquid biopsy market size was estimated at USD 212.4 million in 2025 and is predicted to increase from USD 244.68 million in 2026 to approximately USD 874.34 million by 2035, expanding at a CAGR of 15.2% from 2026 to 2035. Her analysis highlights the increasing adoption of precision oncology, companion diagnostics, early cancer screening, circulating tumor DNA testing, and genomic testing. The research also examines the competitive strategies of key industry participants, including CellBxHealth, Illumina, Inc., Epigenomics AG, QIAGEN, and Thermo Fisher Scientific Inc., shaping the future by increasing cross-border research collaborations, advancements in biomarker discovery, integration into routine clinical practice, and improved healthcare accessibility across the global Middle East liquid biopsy market.
Last Updated : 14 July 2026
Category: Biotechnology
Insight Code: 7011
Format: PDF / PPT / Excel